Current Status of Fertility Preservation Technology in China: Maturity Assessment, Target Population, and Clinical Decision Analysis

👨‍⚕️ Reproductive Physician · Clinical Decision Perspective

In the reproductive medicine clinic, when a patient says, "I want to preserve my fertility," my clinical decision-making path usually involves three steps: the first step is to confirm the medical necessity of fertility preservation—whether it is for elective delayed childbearing or facing the risk of iatrogenic damage; the second step is to assess ovarian reserve function, including AMH, FSH, and antral follicle count; the third step is to select the appropriate technical solution. The intersection of these three steps determines the feasibility and expected outcome of fertility preservation.

I. Maturity of Fertility Preservation Technology in China

China's fertility preservation technology system has developed for nearly two decades, forming a complete technological chain centered on oocyte vitrification, embryo freezing, ovarian tissue freezing, and sperm freezing. From a laboratory perspective, the survival rate after vitrification rewarming in leading domestic reproductive centers has reached 90%–95%, showing no significant difference from top centers in developed countries such as Europe, the United States, and Japan.

It should be clarified that technological maturity does not equal clinical accessibility. China has clear regulatory constraints on the clinical application of fertility preservation, with differences in indications, target populations, and operational standards for different technological pathways. Technology is mature at the technical level, but there are boundaries at the policy level—this is a key prerequisite for understanding the current status of fertility preservation in China.

II. How Physicians View Fertility Preservation Decision-Making

From a clinical decision-making perspective, fertility preservation is not a single technological choice but a multi-factor decision-making process involving medical indications, age window, ovarian reserve, legal compliance, and patient willingness.

When is fertility preservation suitable? The following three groups are the main indications:

• Cancer patients: Freezing oocytes, embryos, or ovarian tissue before radiotherapy or chemotherapy to prevent iatrogenic fertility damage.
• Married women with diminished ovarian reserve: AMH below 1.0 ng/mL, or antral follicle count less than 6, and no immediate pregnancy plans.
• Married women opting for elective delayed childbearing: Under 35 years old with normal ovarian reserve, planning to delay childbirth due to academic, career, or other reasons.

When is it not suitable? The following situations require caution or are not currently recommended:

• Unmarried women (non-medical indication): According to current regulations, domestic reproductive centers cannot perform oocyte freezing for unmarried women without medical indications.
• Age over 40 with AMH below 0.5 ng/mL: Low oocyte yield, poor cost-effectiveness of freezing, clinical pregnancy rate less than 10%.
• Presence of uncontrolled systemic disease or acute infection: The primary condition must be treated first.

III. Fertility Preservation Strategies by Age Group

Age is the most critical variable affecting the outcome of fertility preservation, directly influencing oocyte yield, oocyte quality, chromosome normality rate, and final live birth rate. Strategies and expectations should differ significantly across age groups.

The data in the table above is based on clinical statistics from multiple domestic reproductive centers and is for decision-making reference. Individual variation is significant; specific judgments should combine personal AMH, FSH, and antral follicle count.

IV. Interpretation of Test Indicators: AMH, FSH, and Antral Follicle Count

Ovarian reserve assessment before fertility preservation is the foundation of decision-making. The clinical significance of the three core indicators is as follows:

• AMH (Anti-Müllerian Hormone): Secreted by preantral and small antral follicles, it is the most stable quantitative indicator for assessing ovarian reserve. It is not affected by the menstrual cycle and can be tested at any time. AMH < 1.0 ng/mL indicates diminished ovarian reserve, < 0.5 ng/mL indicates severe diminishment.
• FSH (Follicle-Stimulating Hormone): Tested on days 2–4 of the menstrual cycle, it reflects the ovary's responsiveness to central gonadotropins. FSH > 10 IU/L suggests declining ovarian function, > 15 IU/L indicates significant decline.
• Antral Follicle Count (AFC): Counts the number of antral follicles (2–10mm in diameter) in both ovaries via transvaginal ultrasound. AFC < 6 indicates diminished reserve.

The three indicators should be interpreted comprehensively; no single indicator should be relied upon alone. For example, normal AMH but elevated FSH may suggest ovarian resistance; low AMH but normal AFC may indicate an early stage of decline. Fertility preservation decisions should be based on the complete "ovarian reserve triple test" results.

V. Actual Procedure: Using Oocyte Freezing as an Example

Oocyte freezing is currently one of the most mainstream fertility preservation methods. The complete procedure includes the following stages:

1. Preliminary Assessment and Tests (about 1–2 weeks): Complete AMH, FSH, LH, estradiol, thyroid function, infectious disease screening, chromosome karyotype analysis, transvaginal ultrasound (antral follicle count). Married women need to provide marriage certificate and ID card.
2. Ovarian Stimulation (about 10–14 days): Using an antagonist protocol or short protocol, daily subcutaneous injections of gonadotropins, monitoring follicle development and hormone levels, adjusting medication dosage.
3. Oocyte Retrieval Surgery (about 30 minutes): Transvaginal ultrasound-guided follicle aspiration under intravenous anesthesia. Patients can be discharged after 1–2 hours of observation.
4. Vitrification: Within 2–4 hours after retrieval, oocytes undergo denuding, morphological assessment, and vitrification, then are stored in liquid nitrogen tanks (–196°C).
5. Long-term Storage and Follow-up: Annual payment of storage fees; the center regularly monitors the liquid nitrogen tank status. It is recommended to update health information every 5 years.

How long does it take? From the first visit to completion of freezing, it usually takes 3–5 weeks. The ovarian stimulation phase lasts about 10–14 days, depending on follicle growth rate.

What preparations are needed? ID cards of both partners, marriage certificate (if married), past medical records, and health check-up reports from the last 3 months (especially infectious disease screening and TCT). It is recommended to have an AMH test in advance to assess eligibility for freezing.

VI. Details Most Easily Overlooked

In clinical work, I find that patients focus on the technology itself, but the following details are often overlooked:

• Long-term storage costs for frozen oocytes: The annual storage fee for oocyte freezing in domestic reproductive centers is about 2000–4000 RMB, requiring continuous payment. Some centers offer discounts for the first 3 years, but long-term costs need to be included in financial planning.
• Oocyte freezing ≠ Embryo freezing: The fertilization rate after rewarming for frozen oocytes (about 70%–80%) is lower than for fresh oocytes (85%–90%), while the survival rate after rewarming for frozen embryos is over 95%. Married individuals should prioritize embryo freezing.
• Chromosome abnormality rate increases with age: Oocyte freezing cannot improve oocyte quality. The age at freezing determines the oocyte's chromosome normality rate—about 65% at age 35, dropping to about 40% at age 40.
• Genetic counseling is needed before freezing: If there is a family history of genetic diseases, it is recommended to complete genetic counseling and carrier screening before freezing to avoid the frozen oocytes being unusable in the future.

VII. Common Pitfalls

Based on real patient cases, the following misconceptions most often lead to decision-making errors:

• Misconception 1: "Freezing oocytes guarantees having a child." The final live birth rate from frozen oocytes is affected by multiple factors, including age at freezing, number of oocytes, future partner's fertility, uterine conditions, etc. Freezing is "preserving the possibility," not "guaranteeing the outcome."
• Misconception 2: "Oocytes can be stored indefinitely." Although vitrification can theoretically preserve for decades, clinical data mainly comes from oocytes stored for less than 10 years. Data beyond 10 years is limited, and management risks such as liquid nitrogen tank failure or center closure increase with storage time.
• Misconception 3: "Unmarried women can also freeze their oocytes." As mentioned, current domestic regulations do not allow oocyte freezing for unmarried women without medical indications. Some patients go abroad for oocyte freezing, but the legal and financial risks of cross-border medical care need to be assessed.
• Misconception 4: "Low AMH means no chance at all." Low AMH does not mean no oocytes, only a lower yield. If under 35, even with AMH 0.8 ng/mL, it is still possible to obtain 5–8 oocytes, offering some probability after accumulation.

VIII. Frequently Asked Questions

Question 1: How long can frozen oocytes be stored?
Vitrification in liquid nitrogen at –196°C can theoretically preserve for a long time. Clinical data shows no significant decline in survival and fertilization rates within 10 years. However, it is recommended to use them within 5–10 years to reduce management risks.

Question 2: What is the success rate of frozen oocytes?
It depends on the age at freezing. For oocyte freezing under 35, the live birth rate per single transfer is about 40%–50%; 35–37 years: about 30%–40%; 38–40 years: about 15%–25%. A sufficient number of oocytes (usually 10–15 mature oocytes) is needed to achieve a desirable cumulative live birth rate.

Question 3: Can unmarried women freeze their oocytes?
In mainland China, unmarried women without medical indications cannot undergo oocyte freezing. Cancer patients and others with medical indications are not subject to this restriction. Some unmarried women with clear needs choose to freeze their oocytes in Japan, the United States, or Thailand, but they must bear all costs and risks themselves.

Question 4: What are the costs?
The cost for a single cycle of oocyte freezing in China is about 30,000–50,000 RMB (including tests, ovulation induction drugs, retrieval surgery, and freezing fee), with an annual storage fee of about 2,000–4,000 RMB. Embryo freezing costs slightly less, about 20,000–40,000 RMB. Ovarian tissue freezing is more expensive, about 60,000–100,000 RMB.

Question 5: What are the risks?
The incidence of Ovarian Hyperstimulation Syndrome (OHSS) related to ovulation induction is about 1%–3%. Retrieval surgery carries risks of bleeding, infection, and damage to surrounding organs (each with an incidence below 0.5%). Long-term, there are management risks such as liquid nitrogen leakage and sample mix-ups. Choosing a正规 (standard) reproductive center can minimize these risks.

Question 6: How do I know if I need fertility preservation?
Professional consultation is recommended for anyone meeting any of the following criteria: age ≥ 32 with no pregnancy plans in the next 3 years; AMH < 1.5 ng/mL; diagnosed with cancer requiring radiotherapy/chemotherapy; family history of premature ovarian failure; previous ovarian surgery (e.g., for cysts).

Physician's Advice

From a clinical perspective, the best time for fertility preservation is "now"—but it must be based on individualized medical assessment, not driven by anxiety. I recommend that interested individuals first complete three steps: Step one, check AMH + FSH + antral follicle count to establish your ovarian reserve baseline; Step two, discuss 1–2 specific technical options with a reproductive physician, including expected outcomes, costs, and risks; Step three, combine your fertility time window and family plans to make a rational choice.

The significance of fertility preservation technology is to provide an additional option for future fertility, not to replace current decisions. The technology itself is mature, but how to use it correctly and effectively requires professional medical judgment and clear self-awareness.